Sign in to view content

2-Year Outcomes From Randomized Trials of Anti-VEGF Treatments for Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)

Geeta A. Lalwani, MD

Video
Published 2018

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
3D Dosimetry Simulation for Plaque Selection in Uveal Melanoma: Comparison of COMS Versus Eye Physics Plaques
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2018
Utility of Hypersonic Vitrector Settings During Vitreoretinal Surgery
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more